-+ 0.00%
-+ 0.00%
-+ 0.00%

Accretion Pharmaceuticals' (NSE:ACCPL) Earnings Are Weaker Than They Seem

Simply Wall St·11/15/2026 02:19:51
Listen to the news

Unsurprisingly, Accretion Pharmaceuticals Limited's (NSE:ACCPL) stock price was strong on the back of its healthy earnings report. However, our analysis suggests that shareholders may be missing some factors that indicate the earnings result was not as good as it looked.

earnings-and-revenue-history
NSEI:ACCPL Earnings and Revenue History November 15th 2026

Zooming In On Accretion Pharmaceuticals' Earnings

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

Accretion Pharmaceuticals has an accrual ratio of 0.35 for the year to September 2026. Unfortunately, that means its free cash flow was a lot less than its statutory profit, which makes us doubt the utility of profit as a guide. Over the last year it actually had negative free cash flow of ₹102m, in contrast to the aforementioned profit of ₹131.2m. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of ₹102m, this year, indicates high risk.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Accretion Pharmaceuticals.

Our Take On Accretion Pharmaceuticals' Profit Performance

As we have made quite clear, we're a bit worried that Accretion Pharmaceuticals didn't back up the last year's profit with free cashflow. For this reason, we think that Accretion Pharmaceuticals' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But at least holders can take some solace from the 20% EPS growth in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing Accretion Pharmaceuticals at this point in time. When we did our research, we found 2 warning signs for Accretion Pharmaceuticals (1 is concerning!) that we believe deserve your full attention.

Today we've zoomed in on a single data point to better understand the nature of Accretion Pharmaceuticals' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.